Cellular immunotherapy for refractory hematological malignancies

BACKGROUND: Acute myeloid leukemia (AML) and other aggressive refractory hematological malignancies unresponsive to upfront therapy remain difficult conditions to treat. Often, the focus of therapy is centered on achieving complete remission of disease in order to proceed with a consolidative stem c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Reagan, John L, Fast, Loren D, Safran, Howard, Nevola, Martha, Winer, Eric S, Castillo, Jorge J, Butera, James N, Quesenberry, Matthew I, Young, Carolyn T, Quesenberry, Peter J
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2013
Schlagworte:
Protocol
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3689050/
https://ncbi.nlm.nih.gov/pubmed/23782682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-11-150
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge